It is noteworthy that SMARCA4 loss in human lung cancer is associated with enhanced NRF2 target expression; this effect can be recapitulated in vitro where SMARCA4 knockdown inactivates KEAP1, activates NRF2 and enhances haem oxygenase 1 expression42. Here, SMARCA4 is linked to lung cancer.